With mounting interest in translating GWAS hits from large meta-analyses (meta-GWAS) in diverse 3 clinical settings, evaluating their generalizability in target populations is crucial. Here we consider long-4 term survivors of childhood cancers from the St. Jude Lifetime Cohort Study and show the limited 5 generalizability of 1,376 robust SNP associations reported in the general population across 12 complex 6 anthropometric and cardiometabolic phenotypes (N=2,231; observed-to-expected replication ratio=0.68, 7 P=2.4x10 -9 ). An examination of five comparable phenotypes in a second independent cohort of survivors 8 from the Childhood Cancer Survivor Study corroborated the overall limited generalizability of meta-GWAS 9 hits to survivors (N=4,212, observed-to-expected replication ratio=0.53, P=1.1x10 -16 ). Meta-GWAS hits 10 were less likely to be replicated in survivors exposed to cancer therapies associated with phenotype risk. 11
referred to as meta-GWAS hits) from the general population to specialized clinical populations has not 23 been established for most complex phenotypes. Yet there is growing enthusiasm for utilizing polygenic 24 risk scores to predict disease risk and identify high-risk individuals for targeted interventions; for example, 25 polygenic risk scores have been shown to improve clinical prediction models for cardiovascular disease 26 risk and used to support pharmaceutical interventions to target reductions in low-density lipoprotein levels 27 in high-risk individuals 1, 3 . It is imperative to evaluate the generalizability of established meta-GWAS hits in 28 target populations before adopting such genetic tools built on the GWAS literature. Childhood cancer 29 survivors are one such example of a specialized clinical population that would greatly benefit from 30 knowledge of the generalizability of meta-GWAS hits. Today, approximately one in every 750 individuals 31 is a survivor of childhood or adolescent cancer in the United States 4 . This growing population of survivors 32 differs markedly from the general population. Studies have consistently shown that survivors are at 33 greater risk for a wide range of serious health conditions earlier in life relative to general population or 34 sibling controls, in part due to their exposures to treatments necessary to cure pediatric cancers 4-8 , 35 including chronic cardiovascular and metabolic health conditions that are among the leading causes of 36 morbidity and mortality among survivors 5, [9] [10] [11] [12] . 37 Here we report on the limited generalizability of 1,376 robust meta-GWAS hits (P<5x10 -8 ) 38
identified from the literature for 12 anthropometric and cardiometabolic phenotypes to adult survivors of 39 childhood cancer from the St. Jude Lifetime Cohort Study 7 (SJLIFE; N=2,231, European ancestry), a 40 single-institution retrospective cohort study with longitudinal follow-up of survivors with clinically 41 ascertained health outcomes. We also found limited generalizability of meta-GWAS hits in a second 42
Using phenotype definitions, adjustment covariates, and exclusion criteria that were consistent 70 with reference GWAS (Table 1) , our primary aim was to replicate the 1,376 robust meta-GWAS hits in 71 2,231 adult long-term (≥5-year) survivors of childhood cancer of European ancestry in SJLIFE 7 . Relevant 72 descriptive statistics for the SJLIFE cohort are provided in Table 2 . Most survivors had been exposed to 73 at least one type of chemotherapeutic agent (85.3%) and over half (58.3%) had received radiotherapy; 74 additional adjustments for specific cancer treatment exposures were considered based on the childhood 75 cancer survivorship literature (Table 1 ). There was high correspondence between effect allele frequencies 76 (EAFs) reported in the reference GWAS and the SJLIFE sample, with a median absolute difference of 77 0.99% (IQR=0.47-1.71%). 78
All meta-GWAS hits that were replicated in SJLIFE (P<0.05, with same directions of effect in 79 literature) are listed in Supplementary Table 1 . The results of the meta-GWAS hit replication enrichment 80 analysis in SJLIFE are summarized in Figure 2 and Supplementary Table 2 . Of the 1,376 meta-GWAS 81 hits, we expected to replicate ~279 SNP-phenotype associations across all phenotypes, based on power 82 calculations for replication with SJLIFE sample sizes and SNP EAFs. We replicated only 189 SNP-83 phenotype associations (replication rate=13.7%; 189/1,376 tested) with models adhering to reference 84 GWAS, and 185 SNP-phenotype associations (replication rate=13.4%; 185/1,376 tested) after adjusting 85 for additional covariates relevant to childhood cancer survivors (i.e., cancer treatment exposures, Table  86 1). The Replication Enrichment Ratio (RER), or the ratio of observed-to-expected meta-GWAS hit 87 replication frequencies, across all 12 phenotypes was 0.68 (95% CI: 0.60-0.77, P=2.4x10 -9 ) using models 88 adjusting for reference GWAS covariates only, suggesting that the overall number of meta-GWAS hit 89 replications observed in SJLIFE was significantly less than expected. Significant replication depletion was 90 also observed across all phenotypes using models adjusting for additional covariates relevant to survivors 91 (RER=0.66, 95% CI: 0.58-0.76, P=4.1x10 -10 ). While three phenotypes (WHR, T2D, TG) showed no 92 evidence of replication depletion (RER>1), the remaining nine phenotypes had either significant 93 depletions of meta-GWAS hit replications (RER<1 and P<0.05 for height, BMI, DBP, and obesity) or 94 suggestive evidence of replication depletions (RER<1 and P<0.2 for SBP, HDL, LDL, TC, CAD). 95
We explored alternative definitions of meta-GWAS hit replication in SJLIFE. First, we examined 96 an "extended" replication strategy, under the possible but unlikely scenario that all SNPs involved in the 97 successfully replicated in CCSS survivors with complete genotype, phenotype, and covariate data (up to 126 N=4,212) using models consistent with reference GWAS. All five phenotypes showed significant (P<0.05) 127 or suggestive (P<0.2) meta-GWAS hit replication depletions than expected (Figure 3 , Supplementary  128   Table 2 ), contributing to an overall RER of 0.53 (P=1.1x10 -16 ) using models adhering to reference GWAS. 129
130
Treatments for pediatric cancer and meta-GWAS hit replication depletions in SJLIFE survivors 131
132
We considered whether factors specific to childhood cancer survivors, i.e., exposure to cancer 133 treatments, could "disrupt" robust genetic associations reported in the general population. For the nine 134 phenotypes that showed evidence of meta-GWAS hit replication depletion in SJLIFE (RER<1), we 135 estimated RERs in survivor subgroups stratified by treatment exposure, where treatment exposure was 136 defined as any exposure to therapeutic agents for pediatric cancer associated with the phenotype of 137 interest (Table 1) . We hypothesized that if cancer treatments contribute to phenotypic variation and 138 obscure replications of meta-GWAS hits in survivors, we would not only observe replication depletion in 139 treatment-exposed subgroups, but greater replication depletion in treatment-exposed subgroups than in 140 treatment-unexposed subgroups. 141
We found evidence of replication depletion in treatment-exposed survivor subgroups for seven 142 phenotypes: the height, BMI, TC, obesity, and DBP phenotypes showed significant (P<0.05) replication 143 depletion, while CAD and LDL phenotypes showed suggestive (P<0.2) replication depletion. Among these 144 seven phenotypes, CAD, height, LDL, TC, and DBP showed stronger evidence of replication depletion in 145 treatment-exposed subgroups compared to treatment-unexposed subgroups (i.e., smaller RERs in 146 treatment-exposed subgroups; Figure 4 ). Specifically, CAD, height, LDL, and TC also had the greatest 147 changes in adjusted R 2 (>1%) and the strongest treatment likelihood ratio test P-values (P<1x10 -7 ) when 148 comparing clinical models with and without the relevant treatments, suggesting that replication depletions 149 in meta-GWAS hits are exacerbated in survivors when treatments have greater contributions to the 150 phenotype risk. 151
We speculated that meta-GWAS SNPs with replicated phenotype associations in survivors could 155 have functional/epigenetic annotation enrichments that may distinguish them from SNPs with non-156 replicated associations. Using publicly available bioinformatics data from GTEx 17 and the Roadmap 157 Epigenomics Consortium 18 for functional/epigenetic annotation, we compared the set of 170 SNPs with at 158 least one replicated association with the 12 phenotypes ("replicated SNPs") against the set of 1,061 159 SNPs without any replicated associations ("non-replicated SNPs") from our main analysis in SJLIFE. 160
Similar proportions of replicated and non-replicated SNPs were mapped to RefSeq 19 Supplementary Table 7 ). We also assessed top 167 Reactome 20 biological pathway enrichments for non-overlapping genes mapped to replicated and non-168 replicated SNPs against all other genes in human genome (Supplementary Figure 5 ). For the 79 genes 169 that corresponded with the replicated SNPs, the lead biological pathway enrichments (FDR<0.10) were 170 specific to cardiometabolic phenotypes, i.e., plasma lipoprotein metabolism is connected to serum lipid 171 traits; elastic fiber assembly is related to arterial wall formation and cardiovascular phenotypes; 172 PPARalpha-mediated lipid metabolism is linked to metabolic phenotypes. To contrast, the vast majority of 173 lead biological pathway enrichments (FDR <0.10) for the 466 genes mapped to non-replicated SNPs 174 were related to signal transduction. 175 176 Treatment-DNA methylation patterns and non-replicated meta-GWAS hits in SJLIFE 177
178
We used BIOS Consortium (BIOS QTL 21 ) methylation quantitative trait loci (meQTLs) as a 179 reference resource for ancillary DNA methylation analyses. BIOS QTL includes samples from the Lifelines 180
Cohort Study, which recently reported high meta-GWAS hit replication rates (median=84%) across 32 181 phenotypes 2 . Whole blood cis-meQTLs (≤250 kb between SNP and CpG) from BIOS QTL for any of the 182 1,231 meta-GWAS SNPs of interest (FDR<0.05) were regarded as established phenotype-variant-183 associated cis-meQTLs in the general population. Most meta-GWAS SNPs examined in our main 184 analysis (87.5%, 1,077 SNPs) were mapped to at least one established cis-meQTL (Supplementary 185 Table 8 ). 186
First, we assessed whether established cis-meQTLs in the general population (BIOS QTL) could 187 be generalized to childhood cancer survivors using experimental blood-derived methylome and genotype 188 data from 236 SJLIFE survivors. Despite the small sample size, we successfully validated 5,651 189 established cis-meQTLs for the meta-GWAS SNPs of interest (40.6%; 13,930 tested) in SJLIFE, where 190 validation was defined by SNP-CpG methylation associations with P<0.05 and the same directions of 191 association as reported in BIOS QTL. We further evaluated whether SJLIFE-validated cis-meQTLs could 192 be differentiated by their relationships to SNPs with successful or failed replications in survivors. We 193 discovered that non-replicated SNPs had greater odds of being cis-meQTLs than replicated SNPs 194 (OR=1.66, P=0.02, Supplementary Table 9 ). 195
Next, we investigated the involvement of cis-meQTLs in meta-GWAS hit replications in SJLIFE by 196 considering whether replications were affected by childhood cancer treatments. Specifically, we 197 compared 48 "treatment-sensitive" meta-GWAS SNPs that showed replicated assocations only in the 198 treatment-unexposed subgroup, i.e., in survivors that are more similar to the general population, and 66 199 "treatment-insensitive" meta-GWAS SNPs with robust replications, i.e., replicated in both treatment-200 unexposed and treatment-exposed subgroups. We found greater enrichment for SJLIFE-validated cis-201 meQTLs among treatment-sensitive SNPs (38/42, 90 .5%) compared to treatment-insensitive SNPs 202 (37/57, 64.9%; OR=5.06, P=4.1x10 -3 , Supplementary Table 9 ), suggesting that SNPs with phenotype 203 association replications that were perturbed by treatment exposures in survivors were more likely to 204 involve cis-meQTL mechanisms than SNPs with robust replications. 205
We then explored whether non-replicated meta-GWAS hits in survivors could be attributed to 206 treatment-related disruptions of cis-meQTL profiles. We hypothesized that survivors' exposures to 207 treatments that counter the direction of CpG methylation by a meta-GWAS SNP would reduce the 208 likelihood of replication for the corresponding SNP-phenotype association in survivors. We measured 209 treatment-related disruptions of cis-meQTL profiles by counting the frequency of discordance in the 210 direction of methylation at a CpG site in BIOS QTL for a meta-GWAS SNP and the direction of 211 methylation at the same CpG site for exposure to a specific childhood cancer treatment. We split the 212 4,153 CpG sites linked to the 5,561 SJLIFE-validated cis-meQTLs between replicated and non-replicated 213 SNPs, i.e., 549 "replicated CpGs" versus 3,604 "non-replicated CpGs", respectively. We examined 214 different radiation therapy (RT) and chemotherapeutic exposures ( Supplementary Table 10 ). Non-215 replicated CpGs were enriched for directionally discordant SNP-methylation and treatment-methylation 216 associations for multiple treatment types relative to the replicated CpGs (Supplementary Table 11 ). The 217 non-replicated CpGs showed the strongest enrichment for directionally discordant methylation 218 associations for pelvic RT, with ~54% of non-replicated CpGs bearing directionally discordant methylation 219 associations in contrast to ~29% of replicated CpGs (OR=2.90, P=8.7x10 -4 ). The non-replicated CpGs 220
were also significantly enriched for directionally discordant associations for chest RT (OR=2.70, 221 P=5.3x10 -4 ) and modestly enriched for abdominal RT (OR=1.91, P=0.06). 222
We illustrate these results by describing the failed replication of the T2D risk variant rs1552224 223 (chr11:72722053, GRCh38) in SJLIFE survivors as an example. Multiple meta-GWAS have linked the A 224 allele of rs1552224 with increased T2D risk 22, 23 . However, this association was not replicated among 225 survivors exposed to abdominal or pelvic RT, but was replicated in survivors without these RT exposures 226
( Supplementary Table 12 ). There is growing interest in leveraging knowledge of established meta-GWAS hits though 240 polygenic risk scores (PRS) in specialized clinical populations such as childhood cancer survivors 24 . The 241 suitability of translating this knowledge to such populations, however, depends on the generalizability of 242 general population SNP associations to the clinical population of interest. We evaluated the 243 generalizability of 1,376 SNP associations reported in 46 selected meta-GWAS for 12 anthropometric and 244 cardiometabolic phenotypes in a large cohort of adult survivors of pediatric cancer in SJLIFE using 245 genotypes from whole genome sequencing and clinically ascertained phenotypes. Significantly fewer than 246 expected robust meta-GWAS hits were replicated in SJLIFE survivors, with an observed-to-expected 247 RER of 0.68 (P=2.4x10 -9 ) across all phenotypes. Replication depletion was also observed in a secondary 248 analysis of five comparable phenotypes in an independent cohort of survivors from CCSS. These results 249 suggest that advances in genetic risk prediction (and opportunities for targeted intervention) in vulnerable 250 clinical populations like childhood cancer survivors may ultimately lag behind the general population, and 251 highlight the need for novel genetic association studies in diverse populations. 252
Given that the meta-GWAS hits we tested were robust findings in the general population, i.e., 253 were genome-wide significant (P<5x10 -8 ) and compiled from large meta-GWAS (>10,000 participants), 254 and accompanied by replication, complementary functional annotation, and even experimental validation 255 studies, the limited generalizability of these genetic associations to survivors is unexpected. For 256 comparison, one of the largest recent studies of the generalizability of European-derived GWAS hits in a 257 non-European, multi-ancestral population (N=49,839) observed a more reasonable ~42% replication rate 258 (P<0.05 threshold) across 22 complex continuous phenotypes 25 , despite the accumulating evidence for 259 the poorer predictive accuracy of European-derived PRS in non-Europeans 1 . Discovering that these 260 meta-GWAS hits may only be partially generalizable to survivors is unlikely to be attributable to the 261 methods we employed: we tested associations between measured (not imputed) index SNPs and 262 clinically ascertained phenotypes; we restricted our analyses to survivors of European ancestry; we 263 observed high correspondence between EAFs in SJLIFE and the reference literature; and replication 264 depletion was evaluated accounting for the expected probability of replication based on our sample size. 265
We further investigated the possible but unlikely scenario that non-replications could be primarily due to 266 testing index SNPs that were poor representatives for SNPs causal for phenotype in the same LD block, 267 or non-replication bias due to highly correlated clusters of non-replicating SNPs. These ancillary 268 analyses, along with our analysis of five corresponding phenotypes in a second cohort of survivors in 269 CCSS, corroborate that some of these meta-GWAS hits do not apply to survivors. This analysis is among 270 the first to provide evidence towards a hypothesis described in a recent review of the transferability of 271 PRS across populations, specifically that the generalizability of PRS may also be limited in cohorts with 272 differential environmental exposures 1 . 273
Recent studies have demonstrated that ionizing radiation can induce persistent changes in DNA 274 methylation in cells/tissues targeted by radiation that are dose-dependent [26] [27] [28] [29] [30] . Chemotherapies, e.g., 275 cisplatin 31 and carboplatin 32 , have also been linked to differential methylation of genes involved in cell 276 cycle regulation and DNA repair. In this study, we discovered when cancer treatments had greater 277 contributions to phenotype risk, greater replication depletions than expected were observed in treatment-278 exposed survivor subgroups. Therefore, we assessed whether treatment-related DNA methylation could 279 potentially "disrupt" robust SNP-phenotype relationships reported in the general population among 280 survivors. We found that non-replicated SNPs were significantly enriched for SNPs with cis-meQTLs 281 reported in BIOS QTL that were also validated in a subset of SJLIFE survivors. Furthermore, we 282 discovered a ~5-fold enrichment (P=4.1x10 -3 ) of validated cis-meQTL SNPs among SNPs with 283 replications perturbed by treatments in survivors compared to SNPs that were robustly replicated in 284 survivors. Lastly, enrichments of "disruptive" or directionally discordant methylation associations for chest 285 (OR=2.70, P=5.3x10 -4 ), pelvic (OR=2.90, P=8.7x10 -4 ), and abdominal (OR=1.91, P=0.06) RT among 286
CpGs linked to meta-GWAS SNPs that failed to replicate in SJLIFE survivors were observed. Notably, 287 chronic hematological toxicity has been well-documented for RT to the chest, pelvic, and abdominal fields 288 due to the volume of active bone marrow in these regions 33 , which suggests the DNA methylation 289 patterns we see in the blood-derived methylome data are plausibly related to these RT exposures. Taken 290 together, these results suggest cancer treatments (particularly RT), may disrupt DNA methylation patterns 291 at genomic sites linked to some disease-/trait-associated variants and interfere with their generalizability 292 to survivors. 293
The main limitation of this analysis was the relatively small sample sizes of the survivor cohorts. 294
Our analysis had limited power to detect some SNP-phenotype replications (especially those with small 295 effect sizes), but we estimated the expected number of replications given available power accounting for 296 sample size, reported effect sizes, and sample EAFs and used these estimates to compare observed and 297 expected replication rates. We also performed a secondary analysis of meta-GWAS hit replications in the 298 CCSS cohort which was nearly double the size of the SJLIFE cohort and saw stronger evidence of 299 replication depletions. Another limitation was that we could not combine CCSS and SJLIFE cohorts for all 300 12 phenotypes, since all phenotypes in CCSS are self-reported. Lastly, interpretations of our analyses of 301 SNP and treatment associations with cross-sectional whole blood DNA methylation measurements have 302 several limitations. We were only able to evaluate DNA methylation associations in a small sample of 303 survivors (N=236); however, we did observe a high (~41%) validation rate for established cis-meQTLs 304 (FDR<0.05) reported by BIOS QTL. Similar to the limitations reported in other analyses of DNA 305 methylation associations, we cannot ascertain the extent to which methylation levels at the selected 306
CpGs truly contribute to phenotype variation, or that methylation associations with treatments are strictly 307 attributable to our factor of interest (treatments) versus some other related factor with potential effects on 308 DNA methylation (e.g., primary cancer diagnosis). In addition, evaluating associations between 309 treatments and gene expression levels linked to these CpG sites would be a necessary first step to 310 determine how treatment-related changes in DNA methylation disrupt SNP-phenotype associations. 311
Despite these limitations, our preliminary analyses of DNA methylation in survivors have specific 312 strengths: cumulative prior exposures to RT and chemotherapy are well-documented in our sample, and 313 our analyses only examine established meta-GWAS variants and cis-meQTLs. 314
In summary, we have shown that robust meta-GWAS SNP hits that were observed in general 315 populations for a range of cardiometabolic phenotypes are only partially generalizable to childhood 316 cancer survivor cohorts. Methodologies and applications that rely on established meta-GWAS hits from 317 the general population to predict or clinically surveil some cardiometabolic outcomes or traits may have 318 limited utility in survivors. A plausible explanation for the partial generalizability of robust meta-GWAS hits 319 in survivors is that cancer treatment exposures obscure some genetic associations through epigenetic 320 alterations such as DNA methylation. This phenomenon may also apply to other clinical populations. 321
METHODS 323
Compiling SNP associations with complex traits and diseases 325 and an electronic scale (Scale-Tronix, White Plains, NY); WHR circumferences were taken with a Gulick 370 tape measure. BMI values were adjusted for amputation. Average systolic and diastolic blood pressure 371 (SBP and DBP, respectively; mmHg) values for participants with at least two measurements taken with a 372 calibrated sphygmomanometer after an initial 5-minute rest were used. Fasting blood lipids (mg/dL), 373 including high-density lipoprotein (HDL), calculated low-density lipoprotein (LDL), total cholesterol (TC), 374 and triglycerides (TG) were measured using an enzymatic spectrophotometric assay (Roche Diagnostics, 375
Indianapolis, IN). 376
Coronary artery disease (CAD) and diabetes mellitus were clinically assessed and graded 377 according to the SJCRH-modified NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03 378 classification system 35 . The CTCAE grades used to define cases were based on presence of symptoms 379 and/or relevant medication use. For CAD, use of medications to treat angina symptoms or evidence of 380 abnormal cardiac enzymes, angina and ischemic heart disease, myocardial infarction, percutaneous 381 transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) was used to define 382 cases. Participants with symptomatic diabetes or use of oral medications or insulin to treat diabetes were 383 considered as diabetes mellitus cases; for this analysis, we treated all cases of diabetes mellitus as type 384 2 diabetes cases (T2D) given recent reports suggesting that at least 79% of cases in survivors can be 385 classified as T2D 36 . Brief episodes of diabetes mellitus occurring immediately after treatment or 386 pregnancy were excluded. Obesity was defined as BMI ≥30kg/m 2 , which was consistent with CTCAE-387 based obesity grades. 388
389

CCSS cohort 390 391
The Childhood Cancer Survivor Study 37 (CCSS) is a retrospective cohort study of 5-year 392 childhood cancer survivors with prospective follow-up. Descriptions for CCSS participant eligibility and 393 study design have been published in detail elsewhere 38, 39 . CCSS participants included in this analysis 394 were <21 years of age at primary cancer diagnosis between January 1, 1970 and December 31, 1986, 395 received treatment for pediatric cancer at one of 26 participating study institutions in North America, 396 responded to at least one CCSS questionnaire covering demographics, health conditions, health-related 397 behaviors and health care use; and provided a whole blood, saliva, or buccal sample for DNA 398 sequencing. 399
All phenotypes assessed in CCSS (height, BMI, obesity, CAD, T2D) were self-reported or 400 reported by family proxies for survivors who could not complete surveys, were deceased or <18 years old. 401
For CAD and T2D phenotypes, questionnaire responses related to these conditions (including relevant 402 medication use) were graded using CTCAE v4.03. Information related to chemotherapy, radiotherapy, 403 and surgery was abstracted from medical records. Participants with height values above/below ±4 SD of 404 the sample mean or improbable BMI values (<10, >100 kg/m 2 ) were excluded from analyses. Exclusion 405 criteria or covariates considered in analyses performed in SJLIFE that were not included in CCSS due to 406 missing data included genetic conditions affecting height and hypothalamic-pituitary axis tumor history. 407 Any exposure to glucocorticoids was used as a substitute for glucocorticoid cumulative dosages. All other 408 exclusion criteria, adjustment covariates, and case/phenotype definitions were identical to those applied 409 to the SJLIFE analysis. The SJLIFE genotype data used in this analysis was collected as a part of larger effort to 423 sequence whole genomes of SJLIFE participants 40 . Comprehensive details of DNA sample collection, 424 extraction, sequencing, quality control, and variant mapping have been described previously 40, 41 . Briefly, 425 sequencing for 3,006 samples was completed at the HudsonAlpha Institute for Biotechnology Genomic 426 Raw intensity data was processed with the "minfi" R package 51 , including sample and probe 473 quality controls, background correction, and normalization. Probes were mapped to the GRCh38 build to 474 identify and remove cross-reactive and non-specific probes. We eliminated samples with a low call rate 475 (<95% probes with a detection P value <0.01) or sex discrepancies, along with probes located on sex 476 chromosomes, with low detection rates (<95%), or with SNPs at CpG sites. A total of 689,742 high-quality 477 probes were retained for 300 samples after preliminary quality control. Of the 15,481 probes in BIOS QTL 478 contributing to significant cis-meQTLs with meta-GWAS SNPs of interest, 11,458 probes were available 479 for the current study after quality control for the 236 participants of European ancestry with WGS data that 480 were included in our main analysis. We conducted association tests for the reported genome-wide significant SNPs using phenotype 490 definitions (i.e., units and transformations), exclusion criteria, and adjustment covariates that were 491 consistent with the literature, along with factors relevant to childhood cancer survivors (Table 1) . All 492 regression coefficients, standard errors, and P-values were obtained with linear or logistic regression for 493 quantitative traits or disease outcomes, respectively, using R v3.4.1. All association tests assumed an 494 additive model of genetic inheritance. We used the first 10 principal components as covariates in all 495 association analyses to account for population stratification. Measurements for adjustment covariates or 496 data applied for phenotype transformations that were closest to the measurement or validation date of the 497 trait/outcome were taken. SNP-phenotype associations with P-values <0.05 and the same direction of 498 effect as the reference literature were considered as successful replications. While we also evaluated 499 replications under trait-specific Bonferroni-corrected P-value thresholds, we regarded the P-value 500 threshold of 5% as the primary definition for replication because all tested SNP associations were 501 considered to be robust associations, i.e., published in large-scale meta-GWAS. In SJLIFE, we 502 considered whether reported index SNPs were in high LD with potentially "causal" SNP candidates that 503 would better capture the phenotype association at a given locus or LD block. To this end, we tested all 504 best SNP proxies for non-replicated SNP associations, where best proxies for an index SNP were defined 505 as SNPs in strong LD with the index SNP in the 1000G EUR populations (r 2 >0.8) within a 5-kb window of 506 the index SNP (based on a median LD block size of ~2.5 kb 16 in 1000G EUR). We also assessed 507 observed versus expected replication rates for a pruned set of independent SNP-phenotype associations 508 in SJLIFE given that non-replication rates from clusters of high-LD SNPs without replication signals could 509 inflate replication depletions. Pruning entailed retaining the SNP with the highest EAF in SJLIFE among 510 clusters of SNPs in high LD (r 2 >0.8, 500-kb window in 1000G EUR) for each phenotype. 511 512 Replication power and enrichment analysis 513 514
We used QUANTO v1.2.4 52 to estimate the power for replicating each SNP association reported 515 in the compiled literature with its respective phenotype in SJLIFE and CCSS. Power calculations 516 assumed a 5% significance threshold (as well as a Bonferroni-corrected significance threshold in 517 SJLIFE), phenotype-specific sample sizes, and an additive genetic model. Phenotype-specific power 518 curves for our main analysis accounting for a range of effect allele frequencies and effect sizes are 519 provided in Supplementary Figures 1-4 . We used these power calculations to estimate the replication 520 power for each SNP-phenotype association assuming the effect size reported in reference GWAS and the 521 effect allele frequency observed in the survivor cohorts. We used the same procedure to also estimate 522 replication power for each SNP-phenotype association in treatment-exposed and treatment-unexposed 523 subsamples in SJLIFE, where treatment exposure was defined as any exposure to one or more curative 524 agents for pediatric cancer previously associated with the specific phenotype. 525
In order to evaluate whether the observed replication frequencies were greater or less than 526 expected for each of our phenotypes, we used a Poisson generalized estimating equations (GEE) 527 regression approach with robust variance estimation 53 . We estimated the expected number of replications 528 for each phenotype based on the assumption that each SNP replication may be treated as a Bernoulli 529 random variable with a replication probability equal to its estimated replication power, and under Le 530
Cam's theorem 54 Reactome 20 , and BIOS QTL 21 . We assessed the specificity of enhancer and promoter states for all SNPs 542 with at least one replicated association in the SJLIFE main analysis using the REMC 15-chromatin state 543 annotation data for 127 human cell types. For each cell type, we compared the frequency of 544 enhancer/promoter state overlap in the set of SNPs with replicated associations ("replicated SNPs") 545 against the SNPs without replicated associations ("non-replicated SNPs") in our SJLIFE main analysis. 546
We evaluated nominal enrichment for these regulatory states using P-values obtained from 2-sided 547
Fisher's exact tests. Using GTEx, we counted the number of significant cis-eQTLs (SNPs within ±1 Mb of 548 transcription start sites, FDR≤0.05) for replicated SNPs and non-replicated SNPs and used a 2-sided 549
Fisher's exact test to investigate enrichments in gene expressions among replicated SNPs for each of the 550 48 available cell-/tissue-types. Lastly, we compiled non-overlapping gene sets for replicated SNPs and 551 non-replicated SNPs to conduct a biological pathway enrichment analysis with geneSCF v1.1 55 
and 552
Reactome gene pathway ontologies. A gene was regarded as relevant to a SNP group if a SNP was 553 located within the body of a RefSeq 19 gene. For each biological pathway, the number of genes in our SNP 554 groups with that ontology were compared to the number of genes with that ontology in all remaining 555 genes in the genome. Top biological pathway enrichments were determined using FDR-adjusted P-556 values from 2-sided Fisher's exact tests. Lastly, we used BIOS QTL 21 to identify significant (FDR<0.05) 557 cis-meQTLs linked to our 1,231 meta-GWAS SNPS and tested for enrichments/depletions of SNPs with 558 ≥1 cis-meQTL among the replicated and non-replicated SNPs in our SJLIFE main analysis with two-sided 559
Fisher's exact tests. 560 561 SNP-methylation and treatment-methylation associations 562 563 As a first step, we sought to validate significant (FDR<5%) cis-meQTLs reported in BIOS QTL in 564 our sample of 236 SJLIFE participants with methylation and genotype data. For each established cis-565 meQTL available for testing in SJLIFE, we considered M-values (log2-transformed ratio of the methylated 566 to unmethylated probe intensities) at quality-controlled CpG sites and tested associations between CpG 567 M-values and SNP genotypes assuming an additive inheritance model using linear regression, adjusting 568 for sex, age, and genetic ancestry. Since additional analyses to evaluate potential confounding by inter-569 individual differences in blood cell composition revealed no significant differences in cell type distributions 570 across samples, no adjustment covariates for blood cell composition were considered. Established cis-571 meQTLs (i.e., reported in BIOS QTL with FDR<5%) were defined as validated in SJLIFE for associations 572 with P<0.05 and the same direction of allelic effect. 573
We tested for enrichment of SJLIFE-validated cis-meQTLs among non-replicated SNPs with at 574 least one significant cis-meQTL in BIOS QTL using a 2-sided Fisher's exact test. We also identified a 575 priori 48 "treatment-sensitive" meta-GWAS SNPs (without replications in our main analysis but were 576 replicated in samples without treatment exposures) and 66 "treatment-insensitive" meta-GWAS SNPs 577 (replicated in treatment-unexposed and treatment-exposed samples) and tested for enrichment of 578 validated cis-meQTLs among treatment-sensitive SNPs. Finally, we examined directionally discordant 579 SNP-methylation and treatment-methylation associations for CpGs linked to non-replicated SNPs ("non-580 replicated CpGs") and CpGs linked to replicated SNPs ("replicated CpGs") for the cis-meQTLs we 581 validated in SJLIFE. Among the eight treatment types we considered (cranial, chest, abdominal, and 582 pelvic radiotherapies; anthracycline, corticosteroid, cisplatin, and carboplatin chemotherapies), we limited 583 our analysis to seven treatment types where >5% of the experimental sample was exposed. To ascertain 584 the direction of SNP-CpG methylation associations for CpGs in SJLIFE-validated meQTLs with multiple 585 associated SNPs without arbitrarily assigning a "best" SNP-CpG (i.e., smallest P-value), we used simple 586 majority voting classification to assign the direction of the SNP-methylation association for such CpGs. 587
For each treatment type, treatment dose associations with M-values at CpGs contributing to SJLIFE-588 validated cis-meQTLs were tested with linear regression, adjusting for age and sex. We compared the 589 discordance between directions of SNP-methylation and treatment-methylation associations at each CpG 590 for each of the seven treatment types among replicated and non-replicated CpGs using a two-sided 591
Fisher's exact test. 592 593 DATA AVAILABILITY 594 FIGURES Figure 1 : Diagram describing selection of meta-GWAS and genome-wide significant SNP-phenotype associations for replication in childhood cancer survivor cohorts. All reference GWAS considered in the current study were published between 1/1/2008 -11/20/2017.
NHGRI-EBI GWAS Catalog:
149 GWAS for 12 phenotypes of interest 73 GWAS 46 meta-GWAS Relevant European ancestry GWAS Meta-analyses with replication studies, >10,000 participants 1,415 SNP-phenotype associations ("meta-GWAS hits") in literature 1,376 meta-GWAS hits tested in SJLIFE
Post-quality control in SJLIFE
Genome-wide significant (P<5x10 -8 ) associations Figure 2 : Plots of replication enrichment ratios (RERs) and respective 95% confidence intervals by phenotype in SJLIFE. RERs left of the vertical line corresponding to a RER equal to 1 suggest meta-GWAS hit replication depletion, i.e., observations of fewer replications of meta-GWAS hits than expected. RERs considering adjustment covariates under two different models are presented for each phenotype:
(1) covariates adhering to reference GWAS ("GWAS"), and (2) GWAS covariates along with covariates considered in childhood cancer survivor populations ("Survivor"). Phenotype RERs are color-coded by similarity: anthropometric (blue); blood pressure (green); lipid (yellow), and cardiometabolic disease (red). The observed numbers of replications included in the figure are under the "GWAS" model. The expected numbers of replications are estimated by the sum of the power to replicate each SNP-phenotype association assuming observed SNP effect allele frequencies, the cohort sample size, an additive genetic inheritance model, α=0.05, and effect sizes in reference meta-GWAS. : Plots of phenotype-specific replication enrichment ratios (RERs) and respective 95% confidence intervals in samples unexposed to treatments ("No Treatment") and exposed to treatments ("Treatment"). Treatments were defined as cancer treatments associated with phenotypes. Phenotypes with any evidence of replication depletion (RER<1) in our main analysis that showed either significant (P<0.05) or suggestive (P<0.2) replication depletion in treatment-exposed samples are included in this figure. Sample sizes by exposure strata (NTX-, No Treatment; NTX+, Treatment) are provided, as well as likelihood ratio test P-values representing treatment associations with phenotypes (PTX) and changes in adjusted R 2 (∆RTX 2 ) after removing treatment variables from clinical models. Phenotypes are ordered by ∆RTX 2 values, with larger ∆RTX 2 values reflecting greater treatment influence on phenotype variation. Figure 5 : DNA methylation levels at cg04827223 and percentage of T2D cases by genotype classes for rs1552224 in SJLIFE survivor subgroups with no (a), low-to-moderate (b), and high doses (c) of abdominal or pelvic radiation therapy (RT). No RT dose was defined as 0 Gy, low-to-moderate RT dose was defined by >0 to <20 Gy, and high dose was defined by ≥20 Gy. The upper panels show the observed methylation level relationships with the SNP at the cg04827223 CpG site in the SJLIFE subset with methylome and genotype data (N=236); boxes represent the median and interquartile range (IQR), with whiskers extending from the first or third quartile to 1.5 times the IQR. Methylation level trend by allele dose is shown with median regression lines. Genotype frequencies in this SJLIFE subset were as follows: 1.8% (C/C), 30.8% (C/A), and 67.4% (A/A). The lower panels show the percentage (%) of T2D cases by genotype in SJLIFE survivors in the main analysis (N=2,112), with the following genotype frequencies: 1.9% (C/C), 26 .9% (C/A), and 71.2% (A/A).
